ArticleInfection
Secretory non-pancreatic phopholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2.
Article in Infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality.The Journal of clinical investigation · 2021Trial
- Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation.Intensive care medicine · 2003Trial
- Identification of an Allele-Specific Transcription Factor Binding Interaction that May Regulate PLA2G2A Gene Expression.Bioinformatics and biology insights · 2024Article
- Structural and Functional Aspects of Targeting the Secreted Human Group IIA Phospholipase AMolecules (Basel, Switzerland) · 2020Review
- Lipidomic profile and candidate biomarkers in septic patients.Lipids in health and disease · 2020Review
- An Amperometric Biosensor for the Determination of Bacterial Sepsis Biomarker, Secretory Phospholipase Group 2-IIA Using a Tri-Enzyme System.Sensors (Basel, Switzerland) · 2018Article
- Lipidomic Profiling of Plasma and Erythrocytes From Septic Patients Reveals Potential Biomarker Candidates.Biomarker insights · 2018Article
- New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase.Journal of enzyme inhibition and medicinal chemistry · 2017Article
- Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane.BBA clinical · 2016Article
- Observational
- Transcriptional Regulation of the Group IIA Secretory Phospholipase A2 Gene by C/EBPEmergency medicine : open access · 2013Article
- Acute respiratory distress syndrome in the septic surgical patient.World journal of surgery · 2003Review
- Circulating inflammatory mediators in patients with fever: predicting bloodstream infection.Clinical and diagnostic laboratory immunology · 2001Article
- Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection.Infection and immunity · 2000Article
- GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.Molecular and cellular biochemistry · 1998Article
- Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears.Infection and immunity · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulatory secretory non-pancreatic phospholipase A2 (snp-PLA2) was measured prospectively at the onset (day 0) of severe sepsis in 52 patients as well as on day 1 and 2 in 25 patients, in order to answer two questions: 1) does the snp-PLA2 plasma concentration differ according to the type and severity of infection? 2) what is the relation between snp-PLA2 and other mediators involved in severe sepsis, such as endotoxin, cytokines (TNF alpha, IL-1 beta, IL-6) and thromboxane B2 (the stable metabolite of thromboxane A2)? On day 0, the snp-PLA2 circulatory level was 78 +/- 17 nmol/min/ml in patients with severe sepsis as compared to 3.5 +/- 2 nmol/min/ml in 40 healthy volunteers. There was no statistical difference according to the outcome, the presence of shock, or the type of infection on day 0. However, snp-PLA2 remained elevated or even increased in patients who ultimately died, while it decreased in survivors (p = 0.01 by ANOVA). The cytokine profiles during the 2-day follow-up were similar to that of snp-PLA2, but the differences were not statistically significant between survivors and non-survivors. No correlation was found between snp-PLA2 and other mediators for either initial or peak values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.